Dataset Information

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.

ABSTRACT:

Background

Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC).

Objective

To compare the incidence of liver-related events and mortality between patients aged ≥65 and <65 years.

Methods

Prospective study comparing patients aged ≥65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and HCC was compared between age groups.

Results

Five hundred patients (120 aged ≥65 and 380 aged <65 years) were included. The incidence of liver-related events was 2.62 per 100 patient-years (py) in older and 1.41/100 py in younger patients. All-cause mortality was 3.89 and 1.27/100 py in older and younger patients, respectively. The respective liver-related mortality rates were 1.12 and 0.31/100 py. In patients with cirrhosis (stage F4), all-cause mortality (P = 0.283) and liver-related mortality (P = 0.254) did not differ between groups. All five liver-related deaths were related to multifocal HCC. The incidence of HCC was 1.91 and 1.43 per 100 py in the older and younger groups, respectively (P = 0.747). The diagnosis of HCC was 8 months after the end of treatment.

Conclusions

The incidence of liver-related events and liver-related mortality was low in older people treated with DAAs and was similar to that in younger patients. The extra mortality in people aged ≥65 years treated with DAAs seems to be secondary to non-liver-related causes. These results support the utilization of DAAs in patients aged ≥65 years.

SUBMITTER: Rodriguez-Osorio I

PROVIDER: S-EPMC6546209 | biostudies-literature | 2019

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.

Rodríguez-Osorio Iria I Mena Alvaro A Meijide Héctor H Morano Luis L Delgado Manuel M Cid Purificación P Margusino Luis L Pedreira José Domingo JD Castro Ángeles Á

PloS one 20190603 6

<h4>Background</h4>Direct-acting antivirals (DAAs) are effective in patients aged ≥65 years. However, little is known about the effects of DAAs on survival, liver decompensation and development of hepatocellular carcinoma (HCC).<h4>Objective</h4>To compare the incidence of liver-related events and mortality between patients aged ≥65 and <65 years.<h4>Methods</h4>Prospective study comparing patients aged ≥65 and <65 years treated with DAAs. The incidence of liver-related events and mortality, and ...[more]

PMID: 31158237

Similar Datasets

Project description:BackgroundThe prevalence and risk factors for non-adherence to direct-acting antivirals (DAAs) for chronic hepatitis C virus (HCV) in clinical practice settings are under-studied.Objectives(1) To quantify DAA non-adherence in the total cohort and among subgroups with and without mental health conditions, alcohol use, and substance use, and (2) to investigate patient- and treatment-level risk factor non-adherence.DesignProspective, observational cohort study.ParticipantsA total of 1562 patients receiving DAAs between January 2016 and October 2017 at 11 US medical centers including academic and community practices.Main measuresSelf-reported medication non-adherence, defined as any missed doses in the past 7 days, surveyed early (T2: at 4 ± 2 weeks) and late in treatment (T3: 2-3 weeks prior to end of treatment). Non-adherence to post-treatment follow-up visits was defined as absence of lab results after DAA therapy completion.Key resultsOf 1447 patients, 162 (11%) reported non-adherence at T2 or T3. Medical records indicated 262 (17%) of the 1562 participants had not returned for post-treatment visits. At baseline, 37% of patients reported mental health conditions, 15% reported alcohol use, and 23% reported using substances in the previous year. Baseline characteristics associated with DAA non-adherence included alcohol use (OR 1.96), younger age (< 35 years vs. > 55 years: OR 3.40), non-white race (OR > 2.26), and DAA treatment cohort, but not substance use or mental health condition. Non-adherence to follow-up exhibited association with younger age and a higher baseline overall symptom burden. Among 1287 patients with evaluable sustained virologic response (SVR) data, 53 patients (4%) did not achieve SVR. The bivariate correlation between adherence and SVR was negligible (r = 0.01).ConclusionsDAA non-adherence was low and SVR rates were high. Mental health conditions, substance use, and alcohol use should not disqualify patients from DAA therapy. Patients with alcohol use disorder before DAA therapy initiation may benefit from targeted on-treatment support.

Dataset Information

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.

Background

Objective

Methods

Results

Conclusions

Publications

Liver-related events and mortality among elderly patients with advanced chronic hepatitis C treated with direct-acting antivirals.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets